Connect
MJA
MJA

Substance-related disorders

Letters

Greater scrutiny needed of alcohol companies’ use of brand extensions

Hannah Pierce and Julia Stafford

Med J Aust 2021; 215 (7): 334-335.e1

Editorials

Treatment of alcohol problems: current status and future directions

Paul S Haber, Benjamin C Riordan and Kirsten C Morley

Med J Aust 2021; 215 (7): 315-316 Free

Letters

Recreational nitrous oxide misuse is resulting in serious neurological impairment and persistent disability among users

Simon Mosalski, Anne Tanner and Christine T Shiner

Med J Aust 2021; 215 (5): 237-237.e1

Editorials

Opioid prescribing in Australia: too much and not enough

Adrian J Dunlop, Buddhima Lokuge and Nicholas Lintzeris

Med J Aust 2021; 215 (3): 117-118 Free

Letters

Rapid detection, toxicosurveillance and public health response to stimulant adulteration with acetyl fentanyl

Varan Perananthan, Chris Tremonti, Emily Nash, Thanjira Jiranantakan and Andrew H Dawson

Med J Aust 2021; 214 (11): 533-533.e1

Letters

Buprenorphine: extended‐release formulations “a game changer”!

Katerina Lagios

Med J Aust 2021; 214 (11): 534-534.e1

Perspectives

When will opioid agonist therapy become a normal part of comprehensive health care?

Pallavi Prathivadi and Elizabeth A Sturgiss

Med J Aust 2021; 214 (11): 504-505.e1

Editorials

The challenges of managing both chronic pain and opioid use in general practice

Hester Wilson

Med J Aust 2021; 214 (9): 416-417

Perspectives

Should we be routinely co‐prescribing naloxone for patients on long term opioids?

Pallavi Prathivadi and Suzanne Nielsen

Med J Aust 2021; 214 (9): 403-404.e1

Letters

The impact of Victoria’s real time prescription monitoring system (SafeScript) on a cohort of people who inject drugs

Malcolm Dobbin

Med J Aust 2021; 214 (5): 234-234.e1

Letters

The impact of Victoria’s real time prescription monitoring system (SafeScript) in a cohort of people who inject drugs

Dagnachew M Fetene, Peter Higgs, Suzanne Nielsen, Filip Djordjevic and Paul Dietze

Med J Aust 2021; 214 (5): 234-234.e1

Perspectives

What are people saying on social networking sites about the Australian alcohol consumption guidelines?

Benjamin C Riordan, Daniel T Winter, Paul S Haber, Carolyn A Day and Kirsten C Morley

Med J Aust 2021; 214 (3): 105-107.e1

Perspectives

Screening and brief interventions for harmful alcohol use: where to now?

Chris B Holmwood

Med J Aust 2021; 214 (4): 153-154.e1

Letters

The COVID‐19 response: the health impacts of austerity measures

Shane A Kavanagh, Anthony D LaMontagne and Sharon Brennan‐Olsen

Med J Aust 2021; 214 (3): 142-142.e1 Free

Letters

Alcohol advertisers may be using social media to encourage parents to drink during COVID‐19

Janni Leung, Jason Connor, Leanne Hides and Wayne D Hall

Med J Aust 2020; 213 (4): 188-188.e1 Free

Letters

The impact of Victoria's real time prescription monitoring system (SafeScript) on a cohort of people who inject drugs

Dagnachew M Fetene, Peter Higgs, Suzanne Nielsen, Filip Djordjevic and Paul Dietze

Med J Aust 2020; 213 (3): 141-141.e1

Research

The deleterious effects of cannabis during pregnancy on neonatal outcomes

Luke E Grzeskowiak, Jessica A Grieger, Prabha Andraweera, Emma J Knight, Shalem Leemaqz, Lucilla Poston, Lesley McCowan, Louise Kenny, Jenny Myers, James J Walker, Gustaaf A Dekker and Claire T Roberts

Med J Aust 2020; 212 (11): 519-524 Free

Letters

2,4‐Dinitrophenol exposures and deaths in Australia after the 2017 up‐scheduling

Rose Cairns, Jacques Raubenheimer, Jared A Brown, Kylie McArdle and Nicholas A Buckley

Med J Aust 2020; 212 (9): 434-434.e1

Letters

The impact of an alcohol floor price on critical care admissions in Central Australia

Sarah C Clifford, Kalinda E Griffiths and James A Smith

Med J Aust 2020; 212 (8): 385-385.e1

Letters

The impact of an alcohol floor price on critical care admissions in Central Australia

Paul J Secombe, Michael J Bailey and David Pilcher

Med J Aust 2020; 212 (8): 385-385.e1